Fundraising FoxMemgen
Houston, US · Delaware corporation
Find your way into Memgen
Sign up to see every warm intro you have to Memgen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Memgen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Memgen develops viral, cell-based, and vaccine adjuvant immunotherapies built on its proprietary CD40 ligand technology for treating cancer. Its lead candidate, MEM-288, combines the CD40 ligand with interferon beta and is in phase 1 clinical trials for advanced non-small cell lung cancer.
Founders & leadership
RC
Robert CoatesExecutive
GB
Gregory BrownExecutive
MC
Mark CantwellNamed on SEC filing
Board
PB
Patricia BitarBoard director
CP
Christopher PaganoBoard director
SW
Steven WhitleyBoard director
CL
Casey LoganBoard director
JP
John PoulosBoard director
Reported raises · per SEC filings
Form D private placements$13M disclosed across 6 rounds · 2018–2024
▶$950KraisedDec 2024 · 2 investors · BiotechnologyRule 506(b)
▶$950KraisedDec 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia BitarDirector
- Mark CantwellExecutive Officer
- Christopher PaganoDirector
- Robert CoatesExecutive Officer, Director
- Steven WhitleyDirector
- Gregory BrownExecutive Officer, Director
- Casey LoganDirector
- John PoulosDirector
- Offering amount
- $10M
- Amount sold
- $950K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$625KraisedJun 2023 · 8 investors · BiotechnologyRule 506(b)
▶$625KraisedJun 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven WhitleyDirector
- Christopher PaganoDirector
- Patricia BitarDirector
- Mark CantwellExecutive Officer
- John PoulosDirector
- Gregory BrownExecutive Officer, Director
- Robert CoatesExecutive Officer, Director
- Casey LoganDirector
- Offering amount
- $10M
- Amount sold
- $625K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.8MraisedDec 2021 · 60 investors · BiotechnologyRule 506(b)
▶$9.8MraisedDec 2021 · 60 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia BitarDirector
- Christopher PaganoDirector
- Steven WhitleyDirector
- Kevin CoveneyExecutive Officer
- John PoulosDirector
- Gregory BrownExecutive Officer, Director
- Mark CantwellExecutive Officer, Director
- Robert CoatesExecutive Officer, Director
- Casey LoganDirector
- Offering amount
- $10M
- Amount sold
- $9.8M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$575KraisedJul 2020 · 7 investors · BiotechnologyRule 506(b)
▶$575KraisedJul 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Casey LoganDirector
- Gregory BrownExecutive Officer, Director
- Christopher PaganoDirector
- Robert CoatesExecutive Officer, Director
- Patricia BitarDirector
- Mark CantwellExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $575K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$350KraisedSep 2019 · 3 investors · BiotechnologyRule 506(b)
▶$350KraisedSep 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia BitarDirector
- Gregory BrownDirector
- Robert CoatesExecutive Officer, Director
- Mark CantwellExecutive Officer, Director
- Casey LoganDirector
- Offering amount
- $5M
- Amount sold
- $350K
- Proceeds to insiders
- $360K
- First sale
- Sep 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$715KraisedDec 2018 · 10 investors · BiotechnologyRule 506(b)
▶$715KraisedDec 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert CoatesExecutive Officer, Director
- Mark CantwellExecutive Officer, Director
- Gregory BrownDirector
- Casey LoganDirector
- Offering amount
- $1.9M
- Amount sold
- $715K
- Minimum investment
- $10K
- First sale
- Nov 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.
MetagenomiMetagenomi is a genetic medicines company developing therapies based on gene editing technologies to treat patients with serious diseases. It operates in the biotech sector, working on translational and clinical development of genetic medicine programs.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Companies working in the same space as Memgen.
Frequently asked questions
- What does Memgen do?
- Memgen develops viral, cell-based, and vaccine adjuvant immunotherapies built on its proprietary CD40 ligand technology for treating cancer. Its lead candidate, MEM-288, combines the CD40 ligand with interferon beta and is in phase 1 clinical trials for advanced non-small cell lung cancer.
- How much funding has Memgen raised?
- Memgen has disclosed $13M raised across 6 rounds.
- Where is Memgen headquartered?
- Memgen is headquartered in Houston, US.